50 research outputs found
Levels of DNA methylation vary at CpG sites across the BRCA1 promoter, and differ according to triple negative and "BRCA-like" status, in both blood and tumour DNA
Triple negative breast cancer is typically an aggressive and difficult to treat subtype. It is
often associated with loss of function of the BRCA1 gene, either through mutation, loss of
heterozygosity or methylation. This study aimed to measure methylation of the BRCA1
gene promoter at individual CpG sites in blood, tumour and normal breast tissue, to assess
whether levels were correlated between different tissues, and with triple negative receptor
status, histopathological scoring for BRCA-like features and BRCA1 protein expression.
Blood DNA methylation levels were significantly correlated with tumour methylation at 9 of
11 CpG sites examined (p<0.0007). The levels of tumour DNA methylation were significantly
higher in triple negative tumours, and in tumours with high BRCA-like histopathological
scores (10 of 11 CpG sites; p<0.01 and p<0.007 respectively). Similar results were
observed in blood DNA (6 of 11 CpG sites; p<0.03 and 7 of 11 CpG sites; p<0.02 respectively).
This study provides insight into the pattern of CpG methylation across the BRCA1
promoter, and supports previous studies suggesting that tumours with BRCA1 promoter
methylation have similar features to those with BRCA1 mutations, and therefore may be
suitable for the same targeted therapies
High-risk human papillomavirus (HPV) DNA sequences in metaplastic breast carcinomas of Mexican women
Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial
Role of Androgen Receptors as a Prognostic and Predictive Biomarker in Triple-Negative Breast Cancer
Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer
Elovl6 is a negative clinical predictor for liver cancer and knockdown of Elovl6 reduces murine liver cancer progression
Keratin 15, transcobalamin I and homeobox gene Hox-B13 expression in breast phyllodes tumors: Novel markers in biological classification
10.1007/s10549-011-1555-6Breast Cancer Research and Treatment1321143-151BCTR